Stocks
Seres Therapeutics, Inc.MCRB
NASDAQHealthcareBiotechnology$2.09
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing live biotherapeutic products to treat diseases caused by disruptions in the microbiome. Its lead candidate, SER-109, targets recurrent Clostridioides difficile infection and has shown promise in late-stage trials. Investors track the stock for its potential first-in-class oral microbiome therapy and upcoming regulatory milestones.
52W Range: $2.01-$29.98
Congressional Interest in Seres Therapeutics, Inc. (MCRB)
No congressional trades have been disclosed for Seres Therapeutics, Inc. (MCRB) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading MCRB?
No congressional trades found for this stock.